Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04973007 | Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases | terminated | Phase 4 | 10 | University of Colorado, DenverOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | terminated | Phase 1 / Phase 2 | 95 | TakedaINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT06882746 |
| A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas |
| terminated |
| Phase 1 |
| 14 |
| Boehringer IngelheimINDUSTRY |
| 3 |
| Sep 24, 2026 |
| clinicaltrials |
| NCT05167409 | Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | terminated | Phase 2 | 19 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05930496 | Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors | terminated | N/A | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04034173 | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | terminated | Phase 2 | 3 | Ludwig-Maximilians - University of MunichOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 | terminated | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | terminated | Phase 2 | 41 | Hoffmann-La RocheINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05328908 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer(RELATIVITY-123) | terminated | Phase 3 | 769 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer | terminated | Phase 1 | 8 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03068403 | Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After Neo-adjuvant Chemoradiation - RECT(RECT) | terminated | N/A | 2 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03941366 | Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders | terminated | N/A | 15 | Henry Ford Health SystemOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05526079 | Watchful Waiting for Complete Responders to Therapy in Rectal Cancer | terminated | N/A | 15 | Henry Ford Health SystemOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma(BATTMAN) | terminated | Phase 3 | 21 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | terminated | Phase 1 | 47 | BeOne MedicinesINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | terminated | Phase 1 | 19 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 41 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 41 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 1, 2026 | clinicaltrials |
| NCT04926324 | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | terminated | Phase 1 | 3 | University of IowaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06779669 | Use of Alternative and Complementary Medicine by Colorectal Cancer Patients(ALTERNATIVCCR) | terminated | N/A | 217 | University Hospital, LimogesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer(Neo-POLEM) | terminated | Phase 2 | 3 | University of SouthamptonOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | terminated | Phase 1 | 57 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01148056 | Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer | terminated | N/A | 2 | Massachusetts General HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | terminated | Phase 2 | 7 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT01408407 | Alkagin Paste in the Prevention of Radiation Dermatitis | terminated | Phase 2 | 2 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | May 14, 2026 | clinicaltrials |
| NCT03426371 | Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial | terminated | Phase 3 | 52 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT06149741 | Defunctioning Left-sided Colostomy in Low Anterior Resection for Rectal Cancer(STOMALEFT) | terminated | N/A | 16 | Umeå UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05494658 | Impact of Preoperative Oral Branched-chain Amino Acids on Reducing Postoperative Insulin Resistance. | terminated | N/A | 79 | Sun PengOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation(PANEL) | terminated | N/A | 289 | University Hospital, RouenOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT03876561 | "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer"(CONTICARE) | terminated | N/A | 120 | Nantes University HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers(TEJAS-2) | terminated | Phase 2 | 29 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07479381 | Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study(CLEAR) | terminated | — | 14 | Harbinger HealthINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06034197 | Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy | terminated | Early Phase 1 | 9 | Stephan RogallaOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04523389 | Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients(ExoColon) | terminated | — | 172 | Centre Hospitalier Universitaire DijonOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06181201 | Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer(Neo-Flo-Rect) | terminated | — | 2 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response | terminated | N/A | 28 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners(NeuroPrevPTSD) | terminated | Phase 2 | 19 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials